Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01365169 · ClinicalTrials.gov registry record · NA

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

A NA study of Pancreatic Adenocarcinoma and Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
590
Enrollment target
1
Study location

NCT01365169: Recruiting NA study of Pancreatic Adenocarcinoma and Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.

NCT01365169 is a NA study of Pancreatic Adenocarcinoma and Malignant Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 590 participants, below the 99,456-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01365169, a NA study of Pancreatic Adenocarcinoma and Malignant Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
590 participants
Enrollment target
1
Study location

Study Summary

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.

Interventions

  • BEHAVIORAL Exercise Intervention
  • OTHER Health Telemonitoring

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 590 participants
Start Date 2011-05-25
Est. Completion 2027-06-30
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What NCT01365169 shows while recruiting

NCT01365169 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, below the 99,456-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (99% lower).

The record links to 10 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Exercise Intervention is the first listed.

NCT01365169 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01365169 about?

NCT01365169 is a clinical study titled "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"". The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporati...

What is the current status of trial NCT01365169?

This trial is currently recruiting. It is a NA study. The enrollment target is 590 participants. The study started on 2011-05-25. Estimated completion is 2027-06-30.

What conditions does trial NCT01365169 study?

This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Malignant Neoplasm, Malignant Head and Neck Neoplasm, Recurrent Colorectal Carcinoma, Pancreatic Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT01365169?

The interventions under investigation include: Exercise Intervention (BEHAVIORAL), Health Telemonitoring (OTHER).

Who is sponsoring clinical trial NCT01365169?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01365169 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01365169's enrollment target sits among peer trials

590 8th of 62 higher than 55 of 62 other Pancreatic Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03774758 · 590 participants

    Biomarkers for Risk Stratification in Lung Cancer

  • NCT04747626 · 590 participants · NA

    B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair

  • NCT05722938 · 590 participants · Phase 3

    Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

  • NCT06551142 · 590 participants · Phase 1

    A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01365169, the US trial registry maintained by the National Library of Medicine. NCT01365169 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.